Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 17, 2017
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
[ Mon, Apr 17th 2017
] - WOPRAI
Ed Arce Reiterated (CDTX) at Strong Buy with Decreased Target to $280 on, Apr 17th, 2017
Ed Arce of HC Wainwright & Co., Reiterated "Cidara Therapeutics, Inc." (CDTX) at Strong Buy with Decreased Target from $360 to $280 on, Apr 17th, 2017.
Ed has made no other calls on CDTX in the last 4 months.
There are 3 other peers that have a rating on CDTX. Out of the 3 peers that are also analyzing CDTX, 1 agrees with Ed's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Stephen Brozak of "WBB Securities" Upgraded from Strong Sell to Hold on, Wednesday, February 22nd, 2017
These are the ratings of the 2 analyists that currently disagree with Ed
- Kevin DeGeeter of "Ladenburg Thalmann" Initiated at Strong Buy and Held Target at $225 on, Wednesday, April 12th, 2017
- Paul Matteis of "Leerink Swann" Initiated at Buy and Held Target at $340 on, Wednesday, December 21st, 2016
